Management of psoriasis patients with hepatitis B or hepatitis C virus infection

Table 1 Therapies approved by European Medicines Agency for the treatment of psoriasis

	Recommended doses for adult patients
Conventional DMARDs
Acitretine	0.25-1 mg/kg per day
Cyclosporin a	2-5 mg/kg per day
Methotrxate	10 mg to 25 mg per week
Biologic DMARDs
Infliximab	5 mg/kg at 0, 2 and 6 wk followed by a maintenance regimen of 5 mg/kg every 8 wk
Adalimumab	80 mg initially, 40 mg on day 8, and 40 mg every other week thereafter
Etanercept	50 mg subcutaneously 2 times a week for 3 mo; (starting doses of 50 mg once a week have been shown to be effective); maintenance: 50 mg subcutaneously once a week
Golimumab12	50 mg once a month
Certolizumab pegol12	400 mg at 0, 2 and 4 wk followed by a maintenance regimen of 200 mg every other week
Ustekinumab3	45 mg initially, 45 mg at 4 wk, followed by a maintenance regimen of 45 mg every 12 wk3
Secukinumab2	300 mg at 0, 1, 2, 3, and 4 wk followed by a maintenance regimen of 300 mg every 4 wk. For some patients, a dose of 150 mg may be acceptable

¹Approved for adults with active psoriatic arthritis;

²No data available regarding the administration of patients with HBV or HCV;

³For patients weighing > 100 kg (220 lbs), the recommended dose is 90 mg initially, 90 mg at 4 wk, followed by a maintenance regimen of 90 mg every 12 wk. HBV: Hepatitis B virus; HCV: Hepatitis C virus.